Retrophin, Inc. (RTRX)

20.25
NASDAQ
Prev Close 19.67
Day Low/High 19.72 / 20.93
52 Wk Low/High 8.98 / 21.92
Exchange NASDAQ
Shares Outstanding 50.91B
Market Cap 1.00B
P/E Ratio N/A
Div & Yield N.A. (N.A)
Martin Shkreli Was Just Convicted on 3 Counts of Securities Fraud

Martin Shkreli Was Just Convicted on 3 Counts of Securities Fraud

"Pharma bro" Martin Shkreli was found guilty on three of eight counts of securities fraud.

Retrophin Announces Positive Results for Kidney Disease Drug

Retrophin Announces Positive Results for Kidney Disease Drug

Shares of Retrophin surged Wednesday after announcing positive results for its drug that treats a rare kidney disease.

With Martin Shkreli Long Gone, Retrophin is an 'Interesting Opportunity'

With Martin Shkreli Long Gone, Retrophin is an 'Interesting Opportunity'

Retrophin (RTRX), the biotech company that used to be run by indicted hedge fund manager Martin Shkreki, provides an interesting investment opportunity.

Martin Shkreli: From Boy Wonder to Epic Fail

The meteoric rise of the young, brazen, entrepreneur seemed like it would inevitably end in handcuffs.

Pharma CEO Martin Shkreli Arrested for Fraudulent Misconduct

Pharma CEO Martin Shkreli Arrested for Fraudulent Misconduct

The SEC charged the controversial health care CEO with committing fraud over a five-year period.

Where the Money Was Made the Last 5 Years

Where the Money Was Made the Last 5 Years

Only one fund category (of 20) has beaten the S&P 500 over half a decade.

Today's Reversal Spells Trouble

This market is a mess.